QUOTE(tupai @ Jun 13 2021, 03:15 PM)
from a facebook post he made on Jan 22.QUOTE
Ivermectin (IVM) and COVID-19
Oral Ivermectin is listed under WHO essential medicines from 2019, primarily as an anthelminthic drug used to treat various parasitic infestations.
IVM is cheap, easily available and safe for use, and in Malaysia is only licensed for use in animals.
Laboratory work showed IVM has broad spectrum antiviral properties against RNA and DNA viruses. On that basis, some clinicians have repurposed IVM with other standard of care against COVID-19.
There are now case reports and case series indicative of potential beneficial outcomes if patients are prescribed IVM early in SARS-CoV-2 infection as the mechanism to limit viral load and prevent severe disease progression or person-person transmission.
A pilot study published in the Lancet a few days ago showed some promising results but the authors concluded that the study “warrants further exploration”under larger trials with clinical outcomes in patients with risk factors or more severe disease.
https://www.thelancet.com/.../PIIS2589-5370(20.../fulltext
The current opinion over IVM is that there is insufficient data to support the use for prophylaxis or treatment of COVID-19
https://www.covid19treatmentguidelines.nih.gov/statement.../
https://aci.health.nsw.gov.au/.../20201223-Evidence-Check...
The Institute of Clinical Research and KKM Infectious Disease specialists are in the process of developing a clinical trial on IVM, as well as Favipiravir to further ascertain the efficacy of these medicine. We shall update the outcome in due course.
Oral Ivermectin is listed under WHO essential medicines from 2019, primarily as an anthelminthic drug used to treat various parasitic infestations.
IVM is cheap, easily available and safe for use, and in Malaysia is only licensed for use in animals.
Laboratory work showed IVM has broad spectrum antiviral properties against RNA and DNA viruses. On that basis, some clinicians have repurposed IVM with other standard of care against COVID-19.
There are now case reports and case series indicative of potential beneficial outcomes if patients are prescribed IVM early in SARS-CoV-2 infection as the mechanism to limit viral load and prevent severe disease progression or person-person transmission.
A pilot study published in the Lancet a few days ago showed some promising results but the authors concluded that the study “warrants further exploration”under larger trials with clinical outcomes in patients with risk factors or more severe disease.
https://www.thelancet.com/.../PIIS2589-5370(20.../fulltext
The current opinion over IVM is that there is insufficient data to support the use for prophylaxis or treatment of COVID-19
https://www.covid19treatmentguidelines.nih.gov/statement.../
https://aci.health.nsw.gov.au/.../20201223-Evidence-Check...
The Institute of Clinical Research and KKM Infectious Disease specialists are in the process of developing a clinical trial on IVM, as well as Favipiravir to further ascertain the efficacy of these medicine. We shall update the outcome in due course.
This post has been edited by diffyhelman2: Jun 14 2021, 02:55 AM
Jun 14 2021, 02:54 AM

Quote
0.0428sec
0.37
7 queries
GZIP Disabled